Thrombectomy plus intra-arterial alteplase increases excellent functional outcome to 57.5% at 90 days
Adding Alteplase to Thrombectomy Improves Stroke Recovery in This Trial
This randomized, open-label trial with blinded outcome assessment in 440 patients with acute ischemic stroke found that adding intra-arteria…
A Spanish trial found adding intra-arterial alteplase to thrombectomy increased excellent recovery rates without significantly raising bleed…
Extended-window alteplase increases functional outcomes but raises hemorrhage risk in acute ischemic stroke patients
Giving clot-busting drugs beyond 4.5 hours raises bleeding risk but may improve function
This meta-analysis of 2,050 adults shows intravenous alteplase beyond 4.5 hours improves functional scores but significantly increases sympt…
A large review of 2,050 stroke patients found higher bleeding risk with late clot-busting drugs, though some functional gains appeared.
Ultrasound-facilitated catheter-directed alteplase reduces early recurrence in intermediate-risk pulmonary embolism
New trial shows ultrasound-guided clot-busting drugs help some patients with serious lung clots recover faster and safely
This randomized controlled trial evaluated ultrasound-facilitated, catheter-directed fibrinolysis with alteplase plus anticoagulation versus…
A large study found that using ultrasound to guide clot-busting medicine helped patients with serious lung clots avoid bad outcomes. The tre…
Network meta-analysis compares alteplase, tenecteplase, and JX10 for acute ischemic stroke treatment outcomes
New analysis compares three clot-busting drugs for stroke patients treated up to twenty-four hours after symptoms start
This network meta-analysis evaluated intravenous thrombolytic agents for acute ischemic stroke. Alteplase significantly improved functional …
A large review found one standard drug helped more patients walk again than usual care, while a new drug showed promise but needs more testi…
Tenecteplase linked to higher thrombus migration than alteplase in acute ischemic stroke with EVT
Tenecteplase linked to more clot movement than alteplase in stroke patients
This secondary analysis of a randomized controlled trial in 496 patients with intracranial occlusion found that IV tenecteplase was associat…
A study found tenecteplase caused more clot movement than alteplase in stroke patients. This movement was tied to better recovery odds.
Argatroban plus alteplase shows no daytime benefit but nighttime association with better stroke outcomes
Stroke drug works better at night than in the morning
This post hoc analysis of a phase 3 RCT in 692 patients with acute ischemic stroke found no significant difference in excellent functional o…
Nighttime stroke treatment with argatroban plus alteplase may improve recovery, while daytime use showed no added benefit.
Meta-analysis suggests idarucizumab-enabled thrombolysis is feasible for dabigatran-treated stroke patients after AF ablation
Reversing blood thinners may allow stroke treatment with good safety and recovery
This meta-analysis and case report review examines idarucizumab-enabled intravenous thrombolysis in dabigatran-treated patients with peripro…
Reversing dabigatran before stroke treatment appears safe, showing low bleeding and death rates with recovery similar to standard care.
Meta-analysis models cost-effectiveness of IV alteplase plus thrombectomy for large vessel occlusion stroke
Adding alteplase to stroke surgery is cost-effective when treatment starts within 170 minutes
This meta-analysis models cost-effectiveness using individual patient data from 6 trials involving 2,268 patients across 16 countries.
Adding clot-busting medicine to stroke surgery saves money and improves value when treatment starts within 170 minutes, but benefits fade af…
Cortical Superficial Siderosis Burden Predicts Hemorrhage and Poor Outcomes After Stroke Thrombolysis
New Brain Scan Marker Predicts Bleeding Risk Before Treatment
A substudy of the AcT trial (alteplase versus tenecteplase) evaluated radiological Boston CAA criteria and constituent markers in 482 thromb…
A specific brain scan pattern predicts dangerous bleeding after clot-busting drugs, helping doctors decide who needs fast treatment to save …
Marked hyperglycemia linked to higher parenchymal hematoma risk with bridging therapy versus direct EVT in stroke
High blood sugar linked to bleeding risk after stroke clot removal procedure
A post hoc analysis of 627 patients from the DIRECT-MT trial found that in those with admission glucose >11.1 mmol/L, bridging therapy (alte…
Very high blood sugar levels may increase bleeding risk for stroke patients who receive clot-busting drugs before mechanical clot removal.
Reteplase and non-immunogenic staphylokinase show superior functional outcomes vs alteplase in AIS within 4.5h
Which clot-busting drug works best for stroke? Two newer options may help more people walk and talk normally again
A network meta-analysis of 21 RCTs (n=16,837) found reteplase (18+18 mg) and non-immunogenic recombinant staphylokinase (10 mg) were associa…
Two newer clot-busting drugs help more stroke patients walk and talk normally again without increasing the risk of dying within 90 days.